Shilpa Medicare Q4 Results 2026: Profit Jumps 147% as Record Revenue Signals Strong Growth

Shilpa Medicare Limited reported a strong set of Q4 results 2026, with the pharmaceutical company posting its highest-ever quarterly revenue and EBITDA, driven by robust growth in formulations, APIs, and improving operating leverage.

For the quarter ended March 2026, Shilpa Medicare’s consolidated revenue rose 30% year-on-year to ₹439 crore, compared to ₹338 crore in the same period last year. Gross profit increased 27% to ₹297 crore, while EBITDA climbed 40% to ₹121 crore, pushing EBITDA margin higher to 28% from 26% a year ago.

The standout figure in the Q4 results 2026 was adjusted net profit, which surged 147% YoY to ₹87 crore, up sharply from ₹35 crore in Q4FY25. On a sequential basis, profit also rose 59%, reflecting stronger product sales and better cost efficiency.

For the full fiscal year FY26, the company posted revenue of ₹1,549 crore, marking an 18% increase over FY25. Adjusted PAT came in at ₹232 crore, up 135%, while reported PAT jumped 211% to ₹243 crore. EBITDA reached a record ₹445 crore, with margins expanding to 29%.

The strong Q4 results 2026 were supported by solid performance in the formulations segment, where revenue jumped 54% in the quarter to ₹205 crore, led by domestic growth and the launch of Noduca™ for NAFLD treatment.

Shilpa Medicare also improved its balance sheet strength, with net debt-to-EBITDA falling to 1.4x from 1.6x, while ROCE improved to 17.4%. Looking ahead, investors will watch upcoming launches, including its Rotigotine patch and ADC facility commissioning in FY27, as the company builds momentum in specialty pharma and biologics.

Source: https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf